Filing Flows

Filing Flows › Companies › Biofrontera › Cash flow

Biofrontera cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$1.7M in Q2 2026 · −$7.9M over twelve months

Operating cash flow−$1.7M
Free cash flow−$1.7M

Analysis

In Q2 2026, Biofrontera generated −$1.7M of operating cash flow. That is $1.4M more than in Q2 2025 (−$3.0M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$7.9M; the largest uses were operating cash flow ($7.9M), capital spending ($3K); besides operations, cash came from other investing ($3.0M); the cash balance fell by $2.6M.

Operating cash flow was −$1.7M against net income of −$604K. The largest differences: receivables −$1.7M, payables +$681K, stock-based pay +$263K.

Free cash flow

Biofrontera: free cash flow by quarterBiofrontera: free cash flow by quarter−$1.2MQ3 2024−$1.0MQ4 2024−$4.1MQ1 2025−$3.0MQ2 2025−$3.8MQ3 2025−$2.4MQ4 2025−$75KQ1 2026−$1.7MQ2 2026
Operating cash flow less capital spending.
Biofrontera: operating cash flow against capital spendingBiofrontera: operating cash flow against capital spendingOperating cash flowCapital spending−$1.2M$0Q3 2024−$1.0M$1KQ4 2024−$4.1M$3KQ1 2025−$3.0M$1KQ2 2025−$3.8M−$1KQ3 2025−$2.4M−$1KQ4 2025−$70K$5KQ1 2026−$1.7M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$1.7M, Capital spending $0.

Capital allocation, year by year

Biofrontera: where the cash came from (up) and went (down), by fiscal yearBiofrontera: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$26.7MFY2021: Shares issued $14.9M$14.9MFY2021FY2022: Operating cash flow −$16.2MFY2022: Shares issued $9.4MFY2022: Capital spending −$38K$9.4MFY2022FY2023: Operating cash flow −$24.9MFY2023: Net borrowing $3.9MFY2023: Shares issued $4.5MFY2023: Capital spending −$5K$8.4MFY2023FY2024: Operating cash flow −$10.3MFY2024: Net borrowing −$4.3MFY2024: Shares issued $7.7MFY2024: Capital spending −$10K$7.7MFY2024FY2025: Operating cash flow −$13.4MFY2025: Shares issued $10.8MFY2025: Capital spending −$2K$10.8MFY2025
Over these 5 years operating cash flow totalled −$91.4M; the largest uses were operating cash flow ($91.4M) and net borrowing ($4.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$4.7M
Debtnone
Net cash$4.7M
Cash runway7 months

Biofrontera is burning cash: its operations consume cash, a free cash flow of −$7.9M a year at the current rate against $4.7M of cash and investments: a runway of about 7 months before any new financing.

Where the cash came from and went

Biofrontera: sources (+) and uses (−) of cash, Q2 2026Biofrontera: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$1.7MCash drawn (+) / kept (−)$1.7M
Biofrontera: sources (+) and uses (−) of cash, TTM to Q2 2026Biofrontera: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$7.9MOther investing$3.0MCash drawn (+) / kept (−)$2.6MNot reconciled$2.4MCapital spending−$3K

From profit to cash

Biofrontera: net income to operating cash flow, Q2 2026Biofrontera: net income to operating cash flow, Q2 2026Net income−$604KDepreciation & amortization$65KStock-based pay$263KGains on investments$1KReceivables−$1.7MInventory$79KPayables$681KPrepaid and other assets$77KOperating cash flow−$1.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$1.7M———$1.7M−$1.7M
Q1 2026−$70K−$5K——$75K−$75K
Q4 2025−$2.4M$1K—$2.4M−$3.0M−$2.4M
Q3 2025−$3.8M$1K——$3.8M−$3.8M
Q2 2025−$3.0M−$1K——−$5.5M−$3.0M
Q1 2025−$4.1M−$3K——$4.1M−$4.1M
Q4 2024−$1.0M−$1K−$357K—−$3.0M−$1.0M
Q3 2024−$1.2M—−$298K—$1.5M−$1.2M

Biofrontera: income statement and cash flow

Biofrontera, Q2 2026: revenue $12.0M (+33% year over year), operating margin -4.4%. The chart follows the revenue to costs, profit and cash.

Biofrontera: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.